JP2009519025A5 - - Google Patents

Download PDF

Info

Publication number
JP2009519025A5
JP2009519025A5 JP2008545009A JP2008545009A JP2009519025A5 JP 2009519025 A5 JP2009519025 A5 JP 2009519025A5 JP 2008545009 A JP2008545009 A JP 2008545009A JP 2008545009 A JP2008545009 A JP 2008545009A JP 2009519025 A5 JP2009519025 A5 JP 2009519025A5
Authority
JP
Japan
Prior art keywords
seq
heavy chain
chain variable
variable region
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008545009A
Other languages
English (en)
Japanese (ja)
Other versions
JP5015949B2 (ja
JP2009519025A (ja
Filing date
Publication date
Priority claimed from GBGB0525662.3A external-priority patent/GB0525662D0/en
Application filed filed Critical
Publication of JP2009519025A publication Critical patent/JP2009519025A/ja
Publication of JP2009519025A5 publication Critical patent/JP2009519025A5/ja
Application granted granted Critical
Publication of JP5015949B2 publication Critical patent/JP5015949B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008545009A 2005-12-16 2006-12-14 Ｎｏｇｏを標的とする免疫グロブリン Expired - Fee Related JP5015949B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0525662.3A GB0525662D0 (en) 2005-12-16 2005-12-16 Immunoglobulins
GB0525662.3 2005-12-16
PCT/EP2006/069737 WO2007068750A2 (en) 2005-12-16 2006-12-14 Immunoglobulins directed against nogo

Publications (3)

Publication Number Publication Date
JP2009519025A JP2009519025A (ja) 2009-05-14
JP2009519025A5 true JP2009519025A5 (https=) 2011-11-10
JP5015949B2 JP5015949B2 (ja) 2012-09-05

Family

ID=35736284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008545009A Expired - Fee Related JP5015949B2 (ja) 2005-12-16 2006-12-14 Ｎｏｇｏを標的とする免疫グロブリン

Country Status (30)

Country Link
US (2) US8362208B2 (https=)
EP (2) EP2228391A3 (https=)
JP (1) JP5015949B2 (https=)
KR (1) KR101355118B1 (https=)
CN (1) CN101374863B (https=)
AR (1) AR057239A1 (https=)
AU (1) AU2006325228B2 (https=)
BR (1) BRPI0619855A2 (https=)
CA (1) CA2633501C (https=)
CR (1) CR10099A (https=)
CY (1) CY1113094T1 (https=)
DK (1) DK1960429T3 (https=)
EA (1) EA015536B1 (https=)
ES (1) ES2389380T3 (https=)
GB (1) GB0525662D0 (https=)
HR (1) HRP20120684T1 (https=)
IL (1) IL192086A0 (https=)
JO (1) JO2795B1 (https=)
MA (1) MA30041B1 (https=)
MY (1) MY149492A (https=)
NO (1) NO20082699L (https=)
NZ (1) NZ569143A (https=)
PE (1) PE20071099A1 (https=)
PL (1) PL1960429T3 (https=)
PT (1) PT1960429E (https=)
SI (1) SI1960429T1 (https=)
TW (1) TWI378940B (https=)
UA (1) UA96279C2 (https=)
WO (1) WO2007068750A2 (https=)
ZA (2) ZA200805111B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009258063B2 (en) 2007-06-21 2014-09-25 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
HRP20130699T1 (hr) * 2007-11-02 2013-11-22 Novartis Ag Poboljšane molekule koje se vežu na nogo-a i njihova farmaceutska uporaba
PE20091829A1 (es) 2008-05-06 2009-12-12 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
JP2011527317A (ja) * 2008-07-11 2011-10-27 グラクソ グループ リミテッド Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
KR20150036398A (ko) 2012-07-05 2015-04-07 글락소 그룹 리미티드 근육위축가쪽경화증의 치료에서의 항­ｎｏｇｏ­ａ 항체의 최적 투여 섭생
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
WO2018232144A1 (en) * 2017-06-14 2018-12-20 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
WO2020250204A1 (ko) * 2019-06-13 2020-12-17 프레스티지 바이오파마 피티이. 엘티디. 신규 cthrc1에 특이적 항체 및 이의 용도
WO2021079002A2 (en) 2019-10-24 2021-04-29 Novago Therapeutics Ag Novel anti-nogo-a antibodies
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
EP4355782A1 (en) 2021-06-17 2024-04-24 Petmedix Ltd. Anti canine cd20 antibodies
MX2024004875A (es) 2021-10-21 2024-07-19 Petmedix Ltd Proteinas que comprenden en el dominio extracelular de p75ntr.
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
US20250340659A1 (en) 2022-02-09 2025-11-06 PetMedix Ltd. Therapeutic antibodies
CN119768424A (zh) * 2022-08-22 2025-04-04 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用
GB202217993D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Therapeutic antibodies
AU2024217925A1 (en) 2023-02-09 2025-08-14 Zoetis Services Uk Limited Therapeutic molecules comprising variants of the extracellular domain of p75 neurotrophin receptor (p75ntr)
WO2026041734A1 (en) 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
DK0804419T3 (da) 1994-05-27 2003-11-24 Glaxosmithkline Spa Quinolinderivater som tachykinin NK 3-receptor-antagonister
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
ATE275415T1 (de) 1995-06-27 2004-09-15 Res Foundation Of Cuny Hunter Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
DE69942803D1 (de) 1998-07-22 2010-11-11 Smithkline Beecham Ltd Rotein änhelt, und dafür kodierende cdns
CZ304224B6 (cs) 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
DE10338136A1 (de) 2003-08-15 2005-03-24 European Molecular Biology Laboratory Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
CA2549956C (en) * 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins
JP4782700B2 (ja) * 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor

Similar Documents

Publication Publication Date Title
JP2009519025A5 (https=)
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
JP2014502955A5 (https=)
RU2015143242A (ru) Антитела против gdf8 человека
WO2009086539A3 (en) Treatment and prophylaxis of amyloidosis
NZ733060A (en) Anti-cgrp compositions and use thereof
JP2006506942A5 (https=)
JP2019511222A5 (https=)
JP2018535948A5 (https=)
JP2018506277A5 (https=)
JP2017500018A5 (https=)
RU2017102514A (ru) Гуманизированные анти-тау-антитела
JP2019527543A5 (https=)
IL272674B2 (en) Preparations for use in the treatment or prevention of graft-versus-graft disease or disseminated intravascular hemorrhage or veno-occlusive disease associated with hematopoietic stem cell transplantation
HRP20150799T1 (hr) Sastavi i postupci za protutijela protiv komplementnog proteina c5
EP3008093A1 (en) Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
GEP20115324B (en) Tweak binding antibodies
RU2011137369A (ru) Способы лечения воспаления в нейронной ткани с применением моноклонального антитела или его связывающего фрагмента
JP2019527194A5 (https=)
RU2011152816A (ru) ПРИМЕНЕНИЕ АНТИТЕЛА ПРОТИВ Tau pS422 ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ГОЛОВНОГО МОЗГА
JP2018510617A5 (https=)
CA2618681A1 (en) Identification and engineering of antibodies with variant fc regions and methods of using same
TW201219568A (en) Antibody targeting osteoclast-related protein Siglec-15
JP2019530427A5 (https=)
JP2016502515A5 (https=)